Prognosis and Outcomes of Clinically Diagnosed Cardiac Sarcoidosis Without Positive Endomyocardial Biopsy Findings

Kengo Kusano, Kohei Ishibashi, Takashi Noda, Kenzaburo Nakajima, Kosuke Nakasuka, Satoshi Terasaki, Yusuke Hattori, Tomomi Nagayama, Kazuki Mori, Yoichi Takaya, Koji Miyamoto, Satoshi Nagase, Takeshi Aiba, Satoshi Yasuda, Masafumi Kitakaze, Shiro Kamakura, Yoshikazu Yazaki, Shin ichiro Morimoto, Mitsuaki Isobe, Fumio Terasaki

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)

Abstract

Background: Diagnosis of cardiac sarcoidosis (CS) is sometimes difficult due to a low positive rate of epithelioid granulomas by endomyocardial biopsy (EMB). Accordingly, Japanese guidelines can allow the CS diagnosis using clinical data alone without EMB results (clinical CS) since 2006. However, little is known about prognosis and outcome of clinical CS. Objectives: Purpose of this study was to analyze the prognosis, outcomes, and response to corticosteroid of clinical CS using large-scale cohort survey. Methods: Overall, 422 CS patients (mean age 60 ± 13 years, 68% female, median follow-up period of 5 years), including 345 clinical CS and 77 EMB-positive patients, histologically diagnosed CS (histological CS) by Japanese guidelines, were enrolled and examined. Results: Clinical profile (age, sex, initial cardiac arrhythmias, and abnormal uptake of gallium-67 scintigraphy or 18F-fluorodeoxyglucose positron emission tomography in heart) was similar in both groups. Although clinical CS had better prognosis (P = 0.018) and outcome (all-cause death, appropriate defibrillator therapy, and heart transplantation; P = 0.008), multivariate Cox hazard analysis revealed that left ventricular ejection fraction (LVEF) and sustained ventricular tachycardia history were independently associated with outcome (P < 0.001 and P = 0.002, respectively), but not with the diagnosed CS category. Moreover, similar LVEF recovery after corticosteroid was observed in both groups with low LVEF (≤35%) at the 1-year follow-up period (P < 0.001). Conclusions: In clinical CS according to the Japanese guideline, prophylactic implantable-cardioverter-defibrillator and immunosuppressive therapy are important in patients with low LVEF or ventricular tachycardia history, similar to histological CS.

Original languageEnglish
Pages (from-to)385-395
Number of pages11
JournalJACC: Asia
Volume1
Issue number3
DOIs
Publication statusPublished - Dec 2021
Externally publishedYes

Keywords

  • cardiac sarcoidosis
  • clinical diagnosis
  • histological diagnosis
  • prognosis

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'Prognosis and Outcomes of Clinically Diagnosed Cardiac Sarcoidosis Without Positive Endomyocardial Biopsy Findings'. Together they form a unique fingerprint.

Cite this